A controlled-release formulation of the 5-hydroxytryptamine 3 (5-HT3) antagonist granisetron, in which granisteron is encapsulated in a biodegradable poly(ortho ester) polymer, with antiemetic activity. Upon subcutaneous administration, APF530 slowly erodes and releases the active ingredient granisetron over a period of approximately 5 days. As a selective serotonin receptor antagonist, granisetron competitively blocks the action of serotonin at 5-HT3 receptors, resulting in the suppression of nausea and vomiting. Check for active clinical trials using this agent. (NCI Thesaurus)

Related Posts

Award Winning Physicians

Our Physicians work for you, ensuring the highest standard of care.

Learn More